Precigen, Inc. (PGEN): Net Income
-$250.64M
Year ended 2025-12-31
-$157.71M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$250.64M | n/m | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | -$126.23M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | -$95.90M | n/m | 2026-03-25, From 2023-01-01 |
| 2022-12-31 | $28.32M | n/m | 2025-03-19, From 2022-01-01 |
| 2021-12-31 | -$92.17M | n/m | 2024-03-19, From 2021-01-01 |
| 2020-12-31 | -$170.52M | n/m | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | -$322.32M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$509.34M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$117.02M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$186.61M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$84.49M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$81.82M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$38.98M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$81.87M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$85.28M | n/a | 2014-03-31, From 2011-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Precigen, Inc. (PGEN) | 2025-12-31 | -$250.64M | n/m |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | -$244.09M | n/m |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | -$113.62M | n/m |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | -$377.74M | n/m |
| International Stem Cell Corp (ISCO) | 2025-12-31 | -$418.0K | n/m |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | -$80.61M | n/m |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | -$153.94M | n/m |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | -$299.77M | n/m |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$53.58M | n/m |
Compare PGEN, PRTA, JANX, ZBIO side by side · Screen every company in Pharmaceutical Preparations ↗